Pacira Biosciences
10578 Science Center Drive
Suite 125
San Diego
California
92121
United States
Tel: (858) 625 2424
Website: http://www.pacira.com/
About Pacira Biosciences
At Pacira BioSciences, we have a capable and passionate team of people dedicated to serving our customers in a work environment that encourages collaboration. Our culture inspires and challenges individuals to be effective and efficient in all that they do, and our workforce has a passion for excellence.
OWNERSHIP: Public
Stock Exchange: NASDAQ
STOCK SYMBOL: PCRX
194 articles about Pacira Biosciences
-
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
10/11/2021
Pacira BioSciences, Inc. and Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash.
-
Zilretta is the first treatment approved by the U.S. FDA for OA knee pain that uses extended-release microsphere technology.
-
The U.S. FDA is starting off August with a mix of PDUFA dates for acne products, seizure medications and a new manufacturing process for a non-opioid pain killer. Here’s a look.
-
Spine BioPharma Announces Investment by Pacira Biosciences
4/20/2021
Spine BioPharma, LLC, a company committed to developing non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain caused by degenerative disc disease, today announced a $3 million investment by Pacira Biosciences
-
With its only approved drug product on the line, Pacira Biosciences is fighting back against what it's calling “misrepresentation of the clinical effectiveness” of its non-opioid pain reliever Exparel.
-
New Research: Home and Work Demands Require Women Rapidly Recover After Surgery but Medication Choices Delay their Rebound
7/15/2020
Now more than ever, women undergoing surgery want to spend as little time as possible in the hospital and need to recover quickly to return to their day-to-day activities at home and on the job.
-
Myoscience Announces Agreement to be Acquired by Pacira for up to $220 Million
3/5/2019
Company’s ioveraº System Offers Targeted, Long-Lasting Non-Opioid Pain Management
-
San Diego-based Pacira Pharmaceuticals, a specialty pharmaceutical company, plunked down $220 million to acquire medical device company Myoscience and its non-opioid pain treatment system iovera.
-
Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control
3/5/2019
- Pacira Pharmaceuticals, Inc. (“Pacira”) (NASDAQ: PCRX) and MyoScience, Inc. (“MyoScience”), a privately held medical technology company, today announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira.
-
MEDNAX National Medical Group and Pacira Pharmaceuticals Launch National Enhanced Recovery after Cesarean Surgery (ERACS™) Collaborative to Minimize Opioid Use
6/13/2018
MEDNAX, Inc. is pleased to announce that it has partnered with Pacira Pharmaceuticals, Inc. to address the ongoing use of opioids during and after cesarean surgery
-
Shares of Pacira plunged more than 15 percent this morning after the company revealed the FDA panel's decision.
-
Cancer Treatment Centers of America Teams with Pacira on Innovative Collaboration to Educate Physicians and Patients about Responsible Opioid Use
11/29/2017
The goal of the Opioid Risk Reduction Initiative--an educational effort focused on responsible use and increased awareness of opioid alternatives--is to improve the cancer patient experience through expanded pain management options.
-
Ex-Pacira Exec Joins Bay Area Maverick Therapeutics as CEO
8/10/2017
-
Pacira Announces Timing For Second Quarter 2017 Financial Results Webcast And Conference Call
7/26/2017
-
Pacira Announces Publication Of Phase IV Study Of EXPAREL In Patients Undergoing Total Knee Replacement In The Journal Of Arthroplasty
7/26/2017
-
Pacira Announces Topline Phase III Results For EXPAREL As A Single-Dose Nerve Block
7/25/2017
-
Production Problems Lead Pacira to Cut Jobs in San Diego
7/11/2017
-
Pacira Appoints Mark I. Froimson, M.D., To Board Of Directors
6/15/2017
-
Pacira Announces Proposed Offering Of $300 Million Aggregate Principal Amount Of Convertible Senior Notes
3/7/2017
-
DePuy Synthes Release: Company Announces Exclusive Co-Promotional Agreement With Pacira
1/25/2017